Abstract |
Donor lymphocyte infusion (DLI) can restore durable molecular remission in a high percentage of patients with chronic myeloid leukemia (CML) who have relapses after allogeneic stem cell transplantation, but for patients who do not respond survival is poor. Imatinib mesylate ( STI571) is a specific inhibitor of BCR-ABL tyrosine kinase that can induce hematologic and cytogenetic remissions in patients with CML. We report here a male patient who had a relapse to chronic phase after stem cell transplantation for CML, did not benefit from treatment with DLI, and then was administered STI571 at a dose of 400 mg daily. There was a rapid, complete hematologic response, and complete restoration of donor-type hematopoiesis (100% 46, XX marrow metaphases) was achieved after 6 months of therapy, though RT-PCR studies still detected BCR-ABL transcripts in the blood at low level. This case demonstrates that imatinib mesylate can be highly effective in the management of patients who have relapses after allograft for CML.
|
Authors | Eduardo Olavarria, Charles Craddock, Francesco Dazzi, David Marin, Sarah Marktel, Jane F Apperley, John M Goldman |
Journal | Blood
(Blood)
Vol. 99
Issue 10
Pg. 3861-2
(May 15 2002)
ISSN: 0006-4971 [Print] United States |
PMID | 11986250
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Antineoplastic Agents
- Benzamides
- Enzyme Inhibitors
- Piperazines
- Pyrimidines
- Imatinib Mesylate
- Fusion Proteins, bcr-abl
|
Topics |
- Adult
- Antineoplastic Agents
(therapeutic use)
- Benzamides
- Cytogenetic Analysis
- Enzyme Inhibitors
(therapeutic use)
- Fusion Proteins, bcr-abl
(antagonists & inhibitors)
- Hematopoietic Stem Cell Transplantation
- Humans
- Imatinib Mesylate
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
(drug therapy, genetics, therapy)
- Male
- Neoplasm Recurrence, Local
(drug therapy)
- Piperazines
(therapeutic use)
- Pyrimidines
(therapeutic use)
- Transplantation, Homologous
|